Yale Bulletin and Calendar

December 12, 2003|Volume 32, Number 14|Five-Week Issue



BULLETIN HOME

VISITING ON CAMPUS

CALENDAR OF EVENTS

IN THE NEWS

BULLETIN BOARD

CLASSIFIED ADS


SEARCH ARCHIVES

DEADLINES

DOWNLOAD FORMS

BULLETIN STAFF


PUBLIC AFFAIRS HOME

NEWS RELEASES

E-MAIL US


YALE HOME PAGE


Studies say newer psychiatric
medications not cost-effective

Two Yale studies question the economics of medications in the two most widely prescribed and costly classes of psychiatric medications.

One study found that a new and more expensive antipsychotic drug is not more effective than a less costly, older one, and the second study found that industry-associated economic studies of antidepressants favor the companies' new drugs when determining costs and cost-effectiveness.

Costs and value of newer medications are at the forefront of current debates including the purchase of medications from Canada and the new Medicare coverage of prescriptions.

The first study at 17 Veterans Affairs (VA) hospitals compared an older, pennies-a-day schizophrenia drug with a newer, more expensive one.

There was little advantage to the higher priced drug, according to Dr. Robert Rosenheck, director of the VA's Northeast Program Evaluation Center in West Haven and a professor of psychiatry and public health at the School of Medicine. Rosenheck was the lead author of the study, which appeared in the Nov. 26 issue of the Journal of the American Medical Association.

The study represents the first long-term, rigorously designed experimental study of the newer drug, olanzapine, which has U.S. sales of $2 billion annually. In fiscal 2002, the VA spent $208.5 million overall on atypical antipsychotics -- $106.6 million for olanzapine alone.

The researchers compared haloperidol, a typical antipsychotic, to olanzapine, the most expensive among the newer atypical antipsychotics. The study found no differences between the drugs in reducing schizophrenia symptoms or improving quality of life.

Olanzapine costs more than $8 per day per patient, based on VA figures, compared to about six cents per day for haloperidol.

The second study by Dr. Bruce Baker, deputy director of the Treatment Research Program and assistant professor in the Department of Psychiatry, found that economic studies of newer antidepressants sponsored by drug companies favor the companies' own drugs over the older drugs to a greater extent than studies that are not sponsored by the industry.

In 2002, newer antidepressants were listed as five of the top 20 drugs by sales dollars and accounted for over $9 billion in sales.

There is widespread concern in the scientific community about potential sponsorship influence on research, especially in those studies focusing on the cost or cost-effectiveness of drugs.

Baker's study, in the December issue of the British Journal of Psychiatry, is the first to quantitatively analyze economic studies of psychiatric medications.

-- By Jacqueline Weaver


T H I SW E E K ' SS T O R I E S

John Pepper named V.P. for Finance & Administration

Yale expands Homebuyer Program

Professorship honors former Yale president

Students win Rhodes, Marshall Scholarships

Roland Betts named Corporation's senior fellow

ENDOWED PROFESSORSHIPS

DeVane Lectures to investigate meanings of keywords

Yale is site of state's first high-efficiency fuel cell power plant

Yale department adds a personal touch to holiday giving

Artworks created in captivity donated to Yale Art Gallery

Symposium to explore issues of 'space and race'

Journalists offer perspectives on global events, world leaders

Scientists find oldest definitively male fossil

Group prenatal care benefits preterm infants, study shows

Studies say newer psychiatric medications not cost-effective


Bulletin Home|Visiting on Campus|Calendar of Events|In the News

Bulletin Board|Classified Ads|Search Archives|Deadlines

Bulletin Staff|Public Affairs|News Releases| E-Mail Us|Yale Home